Gabriella Parma

2.5k total citations
53 papers, 1.6k citations indexed

About

Gabriella Parma is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Gabriella Parma has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Reproductive Medicine, 29 papers in Oncology and 14 papers in Obstetrics and Gynecology. Recurrent topics in Gabriella Parma's work include Ovarian cancer diagnosis and treatment (36 papers), PARP inhibition in cancer therapy (15 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Gabriella Parma is often cited by papers focused on Ovarian cancer diagnosis and treatment (36 papers), PARP inhibition in cancer therapy (15 papers) and Endometrial and Cervical Cancer Treatments (12 papers). Gabriella Parma collaborates with scholars based in Italy, United States and Spain. Gabriella Parma's co-authors include Nicoletta Colombo, Vanna Zanagnolo, Alessandra Insinga, Andrea Alberto Lissoni, Michele Peiretti, Ignace Vergote, Cristiana Sessa, Fabio Landoni, Gemma Gatta and M. Lapresa and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Gabriella Parma

51 papers receiving 1.6k citations

Peers

Gabriella Parma
Toshiko Jobo Japan
M. Baekelandt Norway
Vanda Salutari Italy
Joanne Rutgers United States
Monica B. Jones United States
A.G.J. van der Zee Netherlands
Hidekatsu Nakai Japan
Stefan Kommoss Germany
Yasuyuki Hirashima Japan
Leah Prentice Canada
Toshiko Jobo Japan
Gabriella Parma
Citations per year, relative to Gabriella Parma Gabriella Parma (= 1×) peers Toshiko Jobo

Countries citing papers authored by Gabriella Parma

Since Specialization
Citations

This map shows the geographic impact of Gabriella Parma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriella Parma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriella Parma more than expected).

Fields of papers citing papers by Gabriella Parma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriella Parma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriella Parma. The network helps show where Gabriella Parma may publish in the future.

Co-authorship network of co-authors of Gabriella Parma

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriella Parma. A scholar is included among the top collaborators of Gabriella Parma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriella Parma. Gabriella Parma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valenza, Carmine, Eleonora Nicolò, Dario Trapani, et al.. (2024). Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study. The Oncologist. 30(7). 1 indexed citations
2.
Bielo, Luca Boscolo, Matteo Repetto, Edoardo Crimini, et al.. (2024). Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. The Oncologist. 29(7). 560–565. 2 indexed citations
3.
Valenza, Carmine, Dario Trapani, Eleonora Nicolò, et al.. (2024). Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms. ESMO Open. 9(9). 103685–103685. 3 indexed citations
4.
Caruso, Giuseppe, Federica Tomao, Gabriella Parma, et al.. (2023). Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. International Journal of Gynecological Cancer. 33(4). 431–443. 25 indexed citations
5.
Caruso, Giuseppe, et al.. (2023). Myeloid neoplasms post PARP inhibitors for ovarian cancer. International Journal of Gynecological Cancer. 33(4). 598–606. 13 indexed citations
6.
7.
Vitis, Luigi Antonio De, Caterina Fumagalli, Paola Rafaniello Raviele, et al.. (2022). 2022-RA-1289-ESGO Understanding clinical and pathological heterogeneity of endometrial cancer with no specific molecular profile (NSMP). International Journal of Gynecological Cancer. 32. A141–A141. 1 indexed citations
8.
Vitis, Luigi Antonio De, Caterina Fumagalli, Paola Rafaniello Raviele, et al.. (2022). 2022-RA-659-ESGO The role of molecular classification in endometrial cancers with lymph nodes metastasis. International Journal of Gynecological Cancer. 32. A103–A104. 1 indexed citations
9.
Lazzari, Roberta, Giulia Corrao, Gabriella Parma, et al.. (2022). 2022-RA-1028-ESGO Role of radiotherapy in platinum sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment. International Journal of Gynecological Cancer. 32. A290–A291. 1 indexed citations
10.
Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Annals of Oncology. 34(2). 152–162. 27 indexed citations
11.
Lazzari, Roberta, Sara Ronchi, Sara Gandini, et al.. (2018). Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. International Journal of Radiation Oncology*Biology*Physics. 101(3). 650–660. 61 indexed citations
12.
Parma, Gabriella, et al.. (2015). Neoadjuvant chemotherapy in cervical cancer: an update. Expert Review of Anticancer Therapy. 15(10). 1171–1181. 35 indexed citations
13.
Colombo, Nicoletta, Michele Peiretti, Gabriella Parma, et al.. (2010). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 21. v23–v30. 146 indexed citations
14.
Landoni, Fabio, Gabriella Parma, Michele Peiretti, et al.. (2007). Chemo-conization in early cervical cancer. Gynecologic Oncology. 107(1). S125–S126. 60 indexed citations
15.
Colombo, Nicoletta, et al.. (2005). Role of conservative surgery in ovarian cancer: the European experience. International Journal of Gynecological Cancer. 15(s3). 206–211. 33 indexed citations
16.
Floriani, Irene, Alessandro Buda, Maria Grazia Cantù, et al.. (2000). Randomised trial comparing doxorubicin, paclitaxel (AT), versus paclitaxel (T), as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum-based chemotherapy.. Annals of Oncology. 11. 32–32. 5 indexed citations
17.
Colombo, N., Gabriella Parma, Luca Bocciolone, et al.. (2000). Medical therapy of advanced malignant epithelial tumours of the ovary. The Forum. 10(4). 323–332. 5 indexed citations
18.
Zanetta, Gerardo, Gabriella Parma, Maurizio Balestrino, et al.. (1999). Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Annals of Oncology. 10(10). 1171–1174. 41 indexed citations
19.
Gadducci, Angiolo, Fabio Landoni, T Maggino, et al.. (1997). Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. International Journal of Gynecological Cancer. 7(1). 78–83. 14 indexed citations
20.
Lissoni, Andrea Alberto, Gerardo Zanetta, Gabriele A. Losa, et al.. (1996). Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Annals of Oncology. 7(8). 861–863. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiko Jobo Breakdown of academic impact, for papers by M. Baekelandt Breakdown of academic impact, for papers by Vanda Salutari Breakdown of academic impact, for papers by Joanne Rutgers Breakdown of academic impact, for papers by Monica B. Jones Breakdown of academic impact, for papers by A.G.J. van der Zee Breakdown of academic impact, for papers by Hidekatsu Nakai Breakdown of academic impact, for papers by Stefan Kommoss Breakdown of academic impact, for papers by Yasuyuki Hirashima Breakdown of academic impact, for papers by Leah Prentice
Rankless by CCL
2026